Τόμος 4 (1990) – Τεύχος 1 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 4 (1990) – Issue 1 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. PHARMAKON-Press Information Services, Athens, Greece

2. OM Laboratories, Geneva, Switzerland

Accepted for publication: January 15, 1990

pharmakonpress[at]pharmakonpress[.]gr

2.         Ritter, J.M., Blair, J.A., Barrow, S.E., Dollery, C.T.: Release of prostacyclin in vivo and its role in man. Lancet I: 317 (1983)

2a.       Plessas, C.T., Plessas, S.T.: Antiplatelet drugs: clinical pharmacology and pharmacokinetics. Epitheor. Klin. Farmakol. FarmakokineL, Int. Ed., 1: 5 (1987)

3.         Angus, J.A., Cocks, T.M.: Endothelial cell function and blood vessel reactivity. Med. Progr. No. 7: 23 (1989)

4.         Oates, J.A., Falardeau, P., Fitzgerald, G., Branch, R.A., Brash, A.R.: Quantification of urinary prostacyclin metabolites in man: estimates on the rate of secretion of prostacyclin into the general circulation. In: Clinical Pharmacology of Prostacyclin (P.J. Lewis, J. O’Grady, eds), p. 21, Raven Press, New York, 1981

5.         Fitzgerald, G.A., Friedman, LA., Miyamori, J., O’Grady, J., Lewis, P.J.: A double blind placebo controlled crossover study of prostacyclin in man. Life Sci. 25: 665 (1979)

6.         Siegl, A.M., Smith, J.B., Silver, M.J., Nicolaou, K.C., Ahern, D.: Selective binding site for [3H] prostacyclin on platelets. J. Clin. Invest. 63: 215 (1979)

7.         MacDermot, J., Barnes, P.J., Waddell, K.A., Dollery, C.T. Blair, J.A.: Prostacyclin binding to guinea-pig pulmonary receptors. Eur. J. Pharmacol. 75: 127 (1981)

8.         Masotti. G., Poggesi, L., Galanti, G., Trotta, F., Neri-Serneri, G.G. Prostacyclin production in man. In: Clinical Pharmacology of Prostacyclin (P.J. Lewis, J. 0’Grady, eds), p. 9, Raven Press, New York, 1981

9.         Nizankowski, R. et al.: Prostacyclin for ischaemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study. Thromboxane Research 37: 21 (1985)

10.       Belch, J.J.F. et al.: Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud’s syndrome. Lancet 1: 313 (1983)

11.       Huczynski, J. et al.: Double-blind controlled trial of the therapeutic effects of prostacyclin in patients with completed ischaemic stroke. Stroke 16: 810 (1985)

12.       Henriksson, P. et al.: Prostacyclin infusion in patients with acute myocardial infarction. Brit. H. J. 53: 173 (1985)

13.       Barts, R.J.: Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 89: 497 (1986)

14.       Furchgott, R.F. and Zawadski, J.V.: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373 (1980)

15.       Furchgott, R.F.: Role of endothelium in responses of vascular smooth muscle to drugs. Ann. Rev. Pharmac. Tox. 24: 175 (1984)

16.       Radomski, Palmer, R.M.J., Moncada, S.: The anti- aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmac. 92: 639 (1987)

17.       Palmer, R.M.J., Ferrige, A.G., Moncada, S.: Release of nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524 (1987)

18.       Feigl, E.O.: Endothelium-derived relaxing factor may be a protective factor. Nature 331: 490 (1988)

19.       Rubanyi, G.M., Vanhoutte, P.M.: Superoxide anions and. hyperoxia inactivate endothelium-derived relaxing factor. Am. J. Physiol. 250: H822 (1986)

20.       Forstermann, U., Miigge, A., Bode, S.M., Frolich, J.C.: Response of human coronary arteries to aggregating platelets: Importance of endothelium-derived relaxing factor and prostanoids. Circ. Res. 63: 306 (1988)

21.       Furlong, B., Hendersdn, A.H., Lewis, M.J., Smith, J.A.: Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br. J. Pharmac. 90: 687 (1987)

22.       Azuma, H„ Ishikawa, M., Sekizaki, S.: Endothelium-dependent inhibition of platelet aggregation. Br. J. Pharmac. 88: 411 (1986)

23.       Martin, W., Villani, G.M., Jothianandan, D., Furchgott. R.F.: Blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation of rabbit aorta by certain ferrous haemoproteins. J Pharmac. Exp. Ther. 233: 679 (1985)

24.       Gryglewski, R.J., Palmer, R.M.J., Moncada, S.: Superoxide anion plays a role in the breakdown of endothelium-derived vascular relaxing factor. Nature 320: 454 (1986)

25.       Luscher, T.F., Richard, V.: Role protecteur de I ‘endothelium dans la circulation. Med. et Hyg. 48: 161 (1990)

26.       Yanagisawa, M. et al.: A novel potent vasosconstrictor peptide produced by vascular endothelial cells. Nature 332: 411 (1988)

27.       Luscher, T.F., Diederich, D. et al.: Difference between endothelium-dependent relaxation in arterial and venous coronary bypass grafts. N. Engl. J. Med. 319: 462 (1988)

28.       T.F. Luscher (ed.): Endothelial Vasoactive Substances and Cardiovascular Disease, p. 1, Karger Publ., Basel, Switzerland, 1988

29.       Moncada, S.: Biological importance of prostacyclin. Br. J. Pharmac. 76: 3 (1982)

30.       Zhihong, Y. et al.: Endothelium-derived relaxing factor and protection against contractions, induced by histamine and serotonin in the human internal mammary artery and in the saphenous vein. Circulation 80: 1041 (1989)

31.       Papadoppulos, Κ.: Vasomotor actions on the coronary arteries. Epitheor. Klin. Farmakol. FarmakokineL. Int. Ed. 3: 3 (1989)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr